ICLR ICON PLC

Ranbaxy Appoints Dr. Kathleen A. Spreen as Medical Director PRINCETON, N.J., May 5 /PRNewswire/ -- Ranbaxy USA Inc., (RUSA), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has selected Kathleen A. Spreen, DO, MS, MPH, to be Executive Director of Medical and Clinical Affairs. Dr. Spreen comes to Ranbaxy from ICON Clinical Research, Inc. (North Wales, PA), a subsidiary of ICON plc , where she served as Senior Director of Medical Affairs. As Medical Director of RUSA, Dr. Spreen's responsibilities will include providing medical expertise for strategic and business planning, managing medically related issues, overseeing quality and supervising medical staff. Commenting on the appointment, Jeffrey Thomas, Vice president, Brand Marketing and Sales at Ranbaxy USA, Inc., said, "Dr. Spreen is a highly-skilled and experienced professional with a wide breadth of pharmaceutical industry knowledge and experience. As our medical director, she will help to strengthen Ranbaxy's position in the U.S. as an innovative and medically advanced pharmaceutical manufacturer. Her expertise will serve as an invaluable cornerstone for Ranbaxy's continued upward growth." Prior to her work at ICON, Dr. Spreen served as Vice President, Scientific Services, at ApotheCom Associates (Yardley, PA) where she led a team of scientific writers, editors and biostatisticians and managed client relations. Before ApotheCom, Dr. Spreen was the Senior Director of Clinical Research, GI Therapeutic Area at AstraZeneca Pharmaceuticals (Frazier, PA), and earlier, worked at Johnson & Johnson, Wyeth-Ayerst and DuPont-Merck. She served in the U.S. Army Medical Corps in the mid-1980s, finishing her tour as Deputy Commander for Clinical Services at the Kirk U.S. Army Health Clinic (Aberdeen Proving Ground, MD). Dr. Spreen received her DO in 1983 from the Philadelphia College of Osteopathic Medicine. She earned her Masters of Public Health Degree at the Medical College of Wisconsin in 1992. That same year, she was Board Certified in Preventive and Occupational Medicine by the American Osteopathic Board of Preventive Medicine. In 1995, she received her Board Certification in Family Practice from the American Osteopathic Board of Family Physicians. Dr. Spreen is widely published and has lectured and provided testimony extensively, particularly in the areas of occupational health and cost effectiveness. Among her memberships in many professional and scientific organizations, Dr. Spreen is a member of the American Osteopathic Association, the American Osteopathic College of Preventive Medicine, the Medical Society of Delaware, the American Medical Association, the American College of Physician Executives, the American Academy of Pharmaceutical Physicians and the Society of Clinical Research Associates. ABOUT RANBAXY LABORATORIES LIMITED Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 34 countries and manufacturing operations in 7 countries. DATASOURCE: Ranbaxy Pharmaceuticals CONTACT: Charles M. Caprariello, Vice President, Business Development of Ranbaxy Inc., +1-609-720-5615; Janine Lang of RF Binder Partners, +1-212-994-7525, for Ranbaxy

Copyright